中国药房2016，Vol.27Issue(33)：4609-4611,4612,4.DOI:10.6039/j.issn.1001-0408.2016.33.01
我国创新药物国家医保目录准入情况研究
Study on Medicare Directory Access System for Innovative Drugs in China
摘要
Abstract
OBJECTIVE:To provide reference for improving medicare drug directory access system for innovative drugs in Chi-na. METHODS:With entry point of the current status of innovative drugs entering National Basic Medical Insurance,Work Injung Insurance and Maternity Insurance Drug System(Medicare Directcry),the support degree of medicare system for policy of innova-tive drugs in China was studied,descriptive statistics and comparative method were conducted to analyze the numbers and waiting time of the grade 1 drugs in Medicare Directory and compare with other countries to provide corresponding policy recommenda-tions. RESULTS & CONCLUSIONS:The innovative drugs in China suffered from less quantity (only accounted 20.17% to the new drugs approved for marketing over the same period)and long waiting time(the average waiting time of 935 days for entering the directory). Inappropriate selection method,static adjustment mechanism of medicare drug directory and the lack of collabora-tion of policy were the main causes.关键词
创新药物/医保目录/准入Key words
Innovative drugs/Medicare directory/Medicare access分类
医药卫生引用本文复制引用
徐伟,白婕..我国创新药物国家医保目录准入情况研究[J].中国药房,2016,27(33):4609-4611,4612,4.基金项目
国家自然科学基金资助项目 （）
